Diabetes Mellitus, Hyperglycemia, Metabolic Syndrome, Pre-Diabetes
Conditions
Keywords
High blood sugar, High HbA1C, hyperglycemia, Pre-Diabetes, Natural Supplement for Diabetes
Brief summary
The purpose of the study is to evaluate the efficacy and safety of PreCrea® on subjects with higher than normal blood sugar levels.
Detailed description
A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, study to evaluate the efficacy and safety of PreCrea®, a twice-daily dietary supplement in people with higher than normal blood sugar levels.
Interventions
DIETARY_SUPPLEMENTStudy dietary supplement (PreCrea 600 mg capsules)
Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
DIETARY_SUPPLEMENTPlacebo
Sponsors
Joe Fenn
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years to ≤ 65 years 2. Newly diagnosed Male or Female participants with higher than normal blood sugar levels (FPG \>100 mg/dL) on of Pre-Diabetes and Diabetes Mellitus during screening and not on any treatment 3. Ability to understand and willingness to sign and date a written Informed Consent Document at the screening visit before any protocol- specific procedures are performed and willing to adhere to the protocol and entire trial procedures
Exclusion criteria
1. Subjects with Type 1 Diabetes Mellitus 2. Participants on insulin therapy and other oral anti-diabetic agents or having uncontrolled diabetes. 3. Stroke, myocardial infarction, coronary artery bypass graft (CABG) percutaneous transluminal coronary angioplasty (PTCA) or angina pectoris within the last 12 months. 4. Cardiac status New York Heart Association class III-IV 5. Uncontrolled blood pressure \> 150 mmhg systolic and \> 100 mmhg diastolic 6. Impaired renal function as shown by but not limited to serum creatinine ≥ 1.5 mg/dl for males and ≥ 1.4 mg/dl for female 7. Clinically significant peripheral edema 8. Clinical evidence of active liver disease or serum alenine aminotransferase (ALT) or aspartate amino transferase (AST) 2.5 times the upper limit of the normal range (2.5 X ULN) 9. Participants on steroid 10. Pregnancy or lactating women 11. Known hypersensitivity to any of the study drugs 12. Any malignancy within the last 5 years, with exception of adequately treated basal or squamous cell carcinoma of the skin or adequately treated carcinoma insitu. 13. Current addiction or current alcohol abuse or history of substance or alcohol abuse within the last 2 years 14. Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol 15. Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study. Subject unlikely to comply with protocol e.g. uncooperative attitude, inability to return for follow up visits and unlikelihood completing of the study. 16. Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with the completion of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Hemoglobin A1c (Hb A1c) levels | Day 1(Baseline) to Day 90 (End of Study) | Change in HbA1c % from baseline (Day 1) to end of supplementation/treatment after 90 days |
| Safety of Dietary Supplement PreCrea 600 mg twice-daily | Day 1 (Baseline) to Day 90 (End of Study) | Measure changes in Renal Function Tests: Blood Urea Nitrogen (BUN) from baseline (Day 1) to end of study (Day 90); Serum Creatinine from baseline (Day 1) to end of study (Day 90) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Fasting Plasma Glucose (FPG) | Day 1 (Baseline) to Day 90 (End of Study) | Change in FPG % from baseline (Day1) to end of supplementation/treatment after 90 days |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety of Dietary Supplement PreCrea 600 mg twice-daily with Liver Function | Baseline (Day 1) to End of Study (Day 90) | Measure changes in Liver Function Tests: Aspartate Aminotransferase (AST) from baseline (Day 1) to End of Study (Day 90); Alanine Aminotransferase (ALT) from baseline (Day1) to End of Study (Day 90); Alkanine Phosphatase (ALP) from baseline (Day1) to End of Study (Day 90 |
Countries
India
Outcome results
None listed